Literature DB >> 11445478

Pilot study of dietary fat restriction and flaxseed supplementation in men with prostate cancer before surgery: exploring the effects on hormonal levels, prostate-specific antigen, and histopathologic features.

W Demark-Wahnefried1, D T Price, T J Polascik, C N Robertson, E E Anderson, D F Paulson, P J Walther, M Gannon, R T Vollmer.   

Abstract

OBJECTIVES: Dietary fat and fiber affect hormonal levels and may influence cancer progression. Flaxseed is a rich source of lignan and omega-3 fatty acids and may thwart prostate cancer. The potential effects of flaxseed may be enhanced with concomitant fat restriction. We undertook a pilot study to explore whether a flaxseed-supplemented, fat-restricted diet could affect the biomarkers of prostatic neoplasia.
METHODS: Twenty-five patients with prostate cancer who were awaiting prostatectomy were instructed on a low-fat (20% of kilocalories or less), flaxseed-supplemented (30 g/day) diet. The baseline and follow-up levels of prostate-specific antigen, testosterone, free androgen index, and total serum cholesterol were determined. The tumors of diet-treated patients were compared with those of historic cases (matched by age, race, prostate-specific antigen level at diagnosis, and biopsy Gleason sum) with respect to apoptosis (terminal deoxynucleotidyl transferase [TdT]-mediated dUTP-biotin nick end-labeling [TUNEL]) and proliferation (MIB-1).
RESULTS: The average duration on the diet was 34 days (range 21 to 77), during which time significant decreases were observed in total serum cholesterol (201 +/- 39 mg/dL to 174 +/- 42 mg/dL), total testosterone (422 +/- 122 ng/dL to 360 +/- 128 ng/dL), and free androgen index (36.3% +/- 18.9% to 29.3% +/- 16.8%) (all P <0.05). The baseline and follow-up levels of prostate-specific antigen were 8.1 +/- 5.2 ng/mL and 8.5 +/- 7.7 ng/mL, respectively, for the entire sample (P = 0.58); however, among men with Gleason sums of 6 or less (n = 19), the PSA values were 7.1 +/- 3.9 ng/mL and 6.4 +/- 4.1 ng/mL (P = 0.10). The mean proliferation index was 7.4 +/- 7.8 for the historic controls versus 5.0 +/- 4.9 for the diet-treated patients (P = 0.05). The distribution of the apoptotic indexes differed significantly (P = 0.01) between groups, with most historic controls exhibiting TUNEL categorical scores of 0; diet-treated patients largely exhibited scores of 1. Both the proliferation rate and apoptosis were significantly associated with the number of days on the diet (P = 0.049 and P = 0.017, respectively).
CONCLUSIONS: These pilot data suggest that a flaxseed-supplemented, fat-restricted diet may affect prostate cancer biology and associated biomarkers. Further study is needed to determine the benefit of this dietary regimen as either a complementary or preventive therapy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11445478     DOI: 10.1016/s0090-4295(01)01014-7

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  21 in total

Review 1.  Novel techniques for the treatment of localized prostate cancer: evidence of efficacy?

Authors:  Marnie R Robinson; Judd W Moul
Journal:  Curr Urol Rep       Date:  2007-05       Impact factor: 3.092

2.  Enterolactone inhibits insulin-like growth factor-1 receptor signaling in human prostatic carcinoma PC-3 cells.

Authors:  Li-Hua Chen; Jing Fang; Zhijian Sun; Huaixing Li; Ying Wu; Wendy Demark-Wahnefried; Xu Lin
Journal:  J Nutr       Date:  2009-02-11       Impact factor: 4.798

3.  Maternal consumption of canola oil suppressed mammary gland tumorigenesis in C3(1) TAg mice offspring.

Authors:  Gabriela Ion; Juliana A Akinsete; W Elaine Hardman
Journal:  BMC Cancer       Date:  2010-03-06       Impact factor: 4.430

4.  Flaxseed and its components differentially affect estrogen targets in pre-neoplastic hen ovaries.

Authors:  Anushka Dikshit; Chunqi Gao; Carrie Small; Karen Hales; Dale Buchanan Hales
Journal:  J Steroid Biochem Mol Biol       Date:  2016-02-27       Impact factor: 4.292

5.  Flaxseed reduces epithelial proliferation but does not affect basal cells in induced benign prostatic hyperplasia in rats.

Authors:  Ilma Cely de Amorim Ribeiro; Carlos Alberto Soares da Costa; Vivian Alves Pereira da Silva; Lanna Beatriz Neves Silva Côrrea; Gilson Teles Boaventura; Mauricio Alves Chagas
Journal:  Eur J Nutr       Date:  2016-02-08       Impact factor: 5.614

6.  Dietary flaxseed prevents radiation-induced oxidative lung damage, inflammation and fibrosis in a mouse model of thoracic radiation injury.

Authors:  James C Lee; Ryan Krochak; Aaron Blouin; Stathis Kanterakis; Shampa Chatterjee; Evguenia Arguiri; Anil Vachani; Charalambos C Solomides; Keith A Cengel; Melpo Christofidou-Solomidou
Journal:  Cancer Biol Ther       Date:  2009-01-01       Impact factor: 4.742

7.  The Effect of Flaxseed Supplementation on Hormonal Levels Associated with Polycystic Ovarian Syndrome: A Case Study.

Authors:  Debra A Nowak; Denise C Snyder; Ann J Brown; Wendy Demark-Wahnefried
Journal:  Curr Top Nutraceutical Res       Date:  2007       Impact factor: 0.416

8.  Vitexins, nature-derived lignan compounds, induce apoptosis and suppress tumor growth.

Authors:  YingJun Zhou; Yiliang Ellie Liu; JianGuo Cao; GuangYao Zeng; Cui Shen; YanLan Li; MeiChen Zhou; Yiding Chen; Weiping Pu; Louis Potters; Y Eric Shi
Journal:  Clin Cancer Res       Date:  2009-08-11       Impact factor: 12.531

9.  Growth inhibitory effect of low fat diet on prostate cancer cells: results of a prospective, randomized dietary intervention trial in men with prostate cancer.

Authors:  William J Aronson; R James Barnard; Stephen J Freedland; Susanne Henning; David Elashoff; Patricia M Jardack; Pinchas Cohen; David Heber; Naoko Kobayashi
Journal:  J Urol       Date:  2010-01       Impact factor: 7.450

10.  Overcoming challenges in designing and implementing a phase II randomized controlled trial using a presurgical model to test a dietary intervention in prostate cancer.

Authors:  Wendy Demark-Wahnefried; Stephen L George; Boyd R Switzer; Denise C Snyder; John F Madden; Thomas J Polascik; Mack T Ruffin; Robin T Vollmer
Journal:  Clin Trials       Date:  2008       Impact factor: 2.486

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.